COVID-19: The Ivermectin African Enigma.

Area of Science:

• Epidemiology
• Infectious Diseases
• Public Health

Background:

• The low incidence of COVID-19 cases and deaths in some African nations prompted an investigation into potential contributing factors.
• Ivermectin, known for its efficacy against parasitic and viral diseases, has demonstrated in vitro activity against SARS-CoV-2.

Purpose of the Study:

• To compare SARS-CoV-2 infection and death rates in African countries with and without intensive ivermectin mass campaigns for onchocerciasis control.
• To assess the potential impact of ivermectin mass drug administration on COVID-19 outcomes.

Main Methods:

• Comparative analysis of data from 19 African Programme for Onchocerciasis Control (APOC) countries versus 35 non-APOC countries.
• Utilized Generalized Poisson regression models to analyze cumulative SARS-CoV-2 infection and mortality rates, controlling for factors like the Human Development Index (HDI).

Main Results:

• Countries participating in APOC demonstrated a statistically significant 28% lower COVID-19 mortality rate (0.72; 95% CI: 0.67-0.78).
• APOC countries also exhibited an 8% lower SARS-CoV-2 infection rate (0.92; 95% CI: 0.91-0.93) compared to non-APOC countries, after adjusting for confounding variables.

Conclusions:

• A significant reduction in COVID-19 mortality and case incidence was observed in APOC countries.
• The findings support the hypothesis that widespread community ivermectin use, as part of onchocerciasis control, may have inadvertently provided a public health benefit against COVID-19.
• Further research is warranted to confirm the role of ivermectin in mitigating COVID-19 spread and severity.